Division of Cardiology, Ferrarotto Hospital, University of Catania, Italy.
Catheter Cardiovasc Interv. 2011 Oct 1;78(4):650-5. doi: 10.1002/ccd.23015. Epub 2011 Jul 25.
Transcatheter valve therapy is becoming an established treatment for aortic stenosis (AS) and it is very promising for mitral regurgitation (MR). There are no formal reports of percutaneous treatment of both AS and MR in the same patient. Here, we report on the first human cases of successful totally percutaneous management of combined severe AS and MR as a planned staged approach and using MitraClip(®) implantation as a procedure necessitated by an unpredictable complication of self-expanding CoreValve device, respectively.
经导管瓣膜治疗技术已成为主动脉瓣狭窄(AS)的一种成熟治疗方法,对于二尖瓣反流(MR)也极具应用前景。目前尚无在同一患者中同时行经皮治疗 AS 和 MR 的正式报告。在此,我们报告首例成功的人类联合重度 AS 和 MR 的完全经皮治疗病例,分别采用计划分期方法和经皮植入 MitraClip(®)作为自膨式 CoreValve 装置出现不可预测并发症的必要治疗程序。